| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYSLTR1 |
| Uniprot No | Q9Y271 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-337aa |
| 氨基酸序列 | MDETGNLTVS SATCHDTIDD FRNQVYSTLY SMISVVGFFG NGFVLYVLIK TYHKKSAFQV YMINLAVADL LCVCTLPLRV VYYVHKGIWL FGDFLCRLST YALYVNLYCS IFFMTAMSFF RCIAIVFPVQ NINLVTQKKA RFVCVGIWIF VILTSSPFLM AKPQKDEKNN TKCFEPPQDN QTKNHVLVLH YVSLFVGFII PFVIIIVCYT MIILTLLKKS MKKNLSSHKK AIGMIMVVTA AFLVSFMPYH IQRTIHLHFL HNETKPCDSV LRMQKSVVIT LSLAASNCCF DPLLYFFSGG NFRKRLSTFR KHSLSSVTYV PRKKASLPEK GEEICKV |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYSLTR1重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Molecular Cloning and Characterization of Human CysLT1 Receptor*
**作者**：Lynch KR et al.
**摘要**：该研究首次成功克隆并表达了人源CYSLTR1基因，证实其编码的蛋白为半胱氨酰白三烯(CysLT)的功能受体，通过体外重组蛋白实验揭示了其与白三烯D4(LTD4)的高亲和力结合特性，为后续炎症机制研究奠定基础。
2. **文献名称**：*Structural Basis of CysLT1 Receptor Activation and Signal Transduction*
**作者**：Yokomizo T et al.
**摘要**：通过重组CYSLTR1蛋白的体外表达及结构解析，研究揭示了受体与配体结合后的构象变化及下游G蛋白偶联信号通路机制，阐明了其在哮喘等炎症性疾病中的关键作用。
3. **文献名称**：*Functional Characterization of Recombinant CysLT1 Receptor in Airway Smooth Muscle Cells*
**作者**：Figueroa DJ et al.
**摘要**：利用重组CYSLTR1蛋白模型，研究证明其在气道平滑肌细胞中介导白三烯诱导的收缩反应，并通过药理学实验筛选出特异性拮抗剂，为抗哮喘药物开发提供靶点依据。
如需获取全文或更多文献，建议通过PubMed或Sci-Hub等平台检索标题或作者信息。
Cysteinyl leukotriene receptor 1 (CYSLTR1) is a G protein-coupled receptor (GPCR) that plays a critical role in mediating inflammatory responses. It binds cysteinyl leukotrienes (CysLTs), lipid mediators derived from arachidonic acid metabolism, including LTC4. LTD4. and LTE4. These molecules are implicated in bronchoconstriction, vascular permeability, and immune cell recruitment, making CYSLTR1 a key target in asthma, allergic rhinitis, and other inflammatory disorders. The receptor signals primarily through Gq and Gi/o proteins, activating pathways such as phospholipase C (PLC)-IP3 and MAP kinase cascades.
Recombinant CYSLTR1 protein is engineered for in vitro studies to elucidate its structure-function relationships, ligand interactions, and signaling mechanisms. Typically produced in mammalian expression systems (e.g., HEK293 or CHO cells), the recombinant protein retains post-translational modifications essential for ligand binding and receptor activity. It is often tagged with fluorescent or affinity markers (e.g., His-tag, FLAG) to facilitate purification and detection. Researchers use this tool to screen antagonists (e.g., montelukast, a asthma drug), characterize mutations affecting receptor activity, or develop antibodies. Its study also extends to cancer research, as CysLT signaling may influence tumor progression. The availability of recombinant CYSLTR1 accelerates drug discovery and mechanistic studies, bridging gaps between cellular models and therapeutic applications.
×
